Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...

Every investor in Pfizer Inc. (NYSE:PFE) should be aware of the most powerful shareholder groups. With 66% stake, ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Novo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from Pfizer. The move, announced Thursday, escalates the competition between the two ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It projected revenue between $59.5 billion and $62.5 billion; at the midpoint, ...

SHANGHAI, CHINA - 2025/11/08: The Pfizer logo is presented at the 8th China International Import Expo. (Photo by Sheldon Cooper/SOPA Images/LightRocket via Getty Images) Pfizer (PFE) is encountering ...

Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells ...

In early January 2026, Pfizer Inc. and Boltz, PBC announced a collaboration to apply biomolecular AI foundation models to ...

Pfizer said revenue should come in at the lower end of its guidance for this year, while it expects less revenue in 2026 than in 2025, as the drugmaker’s efforts to remake its business continue to ...